The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro
Open accessAbstract
Slow-growing bacteria and biofilms are notoriously tolerant to antibiotics. Oritavancin is a lipoglycopeptide with multiple mechanisms of action that contribute to its bactericidal action against exponentially growing gram-positive pathogens, including the inhibition of cell wall synthesis and perturbation of membrane barrier function. We sought to determine whether oritavancin could eradicate cells known to be tolerant to many antimicrobial agents, that is, stationary-phase and biofilm cultures of Staphylococcus aureus in vitro. Oritavancin exhibited concentration-dependent bactericidal activity against stationary-phase inocula of methicillin-susceptible S. aureus(MSSA) ATCC 29213, methicillin-resistant S. aureus(MRSA) ATCC 33591, and vancomycin-resistant S. aureus(VRSA) VRS5 inoculated into nutrient-depleted cation-adjusted Mueller-Hinton broth. As has been described for exponential-phase cells, oritavancin induced membrane depolarization, increased membrane permeability, and caused ultrastructural defects including a loss of nascent septal cross walls in stationary-phase MSSA. Furthermore, oritavancin sterilized biofilms of MSSA, MRSA, and VRSA at minimal biofilm eradication concentrations (MBECs) of between 0.5 and 8 μg/ml. Importantly, MBECs for oritavancin were within 1 doubling dilution of their respective planktonic broth MICs, highlighting the potency of oritavancin against biofilms. These results demonstrate a significant activity of oritavancin against S. aureus in phases of growth that exhibit tolerance to other antimicrobial agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bacterial Biofilms: A Common Cause of Persistent Infections
Costerton, J. W., Stewart, P. S., & Greenberg, E. P. (1999) · Science · doi:10.1126/science.284.5418.1318 · Cited by 12,167 · cited 1×
“Infections in which bacteria are either slow growing, dormant, or in a biofilm pose a serious clinical challenge for therapy because cells in these states exhibit tolerance to the activity of antimicrobial agents (15).”
BackgroundBiofilms: Survival Mechanisms of Clinically Relevant Microorganisms
Donlan, R. M., & Costerton, J. W. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.2.167-193.2002 · Cited by 6,644
Persister cells, dormancy and infectious disease
Lewis, K. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1557 · Cited by 2,052 · cited 2×
“Furthermore, it is thought that these tolerant cells are protected from immune clearance in vivo by the biofilm slime matrix and ultimately give rise to relapse infections by reseeding the biofilm once drug levels drop below their antibacterial concentration (27).”
Background
Cited by
Hurdle, J. G., O'Neill, A. J., Chopra, I., & Lee, R. E. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2474 · Cited by 871
Gram-positive bacterial cell envelopes: The impact on the activity of antimicrobial peptides
Malanovic, N., & Lohner, K. (2016) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2015.11.004 · Cited by 586
Bacterial Biofilm Eradication Agents: A Current Review
Verderosa, A. D., Totsika, M., & Fairfull-Smith, K. E. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00824 · Cited by 555
Antimicrobial Peptides Targeting Gram-Positive Bacteria
Malanovic, N., & Lohner, K. (2016) · Pharmaceuticals · doi:10.3390/ph9030059 · Cited by 420
Management of multidrug-resistant enterococcal infections
Arias, C. A., Contreras, G. A., & Murray, B. E. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03214.x · Cited by 388
New Lipoglycopeptides: A Comparative Review of Dalbavancin, Oritavancin and Telavancin
Zhanel, G. G., Calic, D., Schweizer, F., Zelenitsky, S., Adam, H., Lagacé-Wiens, P. R. S., Rubinstein, E., Gin, A. S., Hoban, D. J., & Karlowsky, J. A. (2010) · Drugs · doi:10.2165/11534440-000000000-00000 · Cited by 352
Orthopaedic biofilm infections
Zimmerli, W., & Sendi, P. (2017) · APMIS · doi:10.1111/apm.12687 · Cited by 338
Cyclic peptide drugs approved in the last two decades (2001–2021)
Zhang, H., & Chen, S. (2022) · RSC Chemical Biology · doi:10.1039/d1cb00154j · Cited by 319
Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections
Corey, G. R., Kabler, H., Mehra, P., Gupta, S., Overcash, J. S., Porwal, A., Giordano, P., Lucasti, C., Perez, A., Good, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310422 · Cited by 305
Self-citationHarrison, J. J., Stremick, C. A., Turner, R. J., Allan, N. D., Olson, M. E., & Ceri, H. (2010) · Nature Protocols · doi:10.1038/nprot.2010.71 · Cited by 286
The antimicrobial potential of cannabidiol
Blaskovich, M. A. T., Kavanagh, A. M., Elliott, A. G., Zhang, B., Ramu, S., Amado, M., Lowe, G. J., Hinton, A. O., Pham, D. M. T., Zuegg, J., et al. (2021) · Communications Biology · doi:10.1038/s42003-020-01530-y · Cited by 283
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Important new therapies for methicillin-resistant Staphylococcus aureus
Bassetti, M., Carnelutti, A., Castaldo, N., & Peghin, M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1675637 · Cited by 21
Metadata
- Authors
- Belley, A., Neesham-Grenon, E., McKay, G., Arhin, F. F., Harris, R., Beveridge, T., Parr, T. R., & Moeck, G.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-03
- Volume
- 53
- Issue
- 3
- Pages
- 918-925
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2068336213
- Cited by
- 178
- References
- 3
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.